Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina    ILMN

ILLUMINA (ILMN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Illumina : Files New Patent Infringement Suit Against Premaitha Health plc

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2017 | 03:04pm CEST

Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief.

The new suit accuses Premaitha’s IONA® Test of infringing European Patent (UK) 1 524 321 B2 titled, “Non-invasive Detection of Fetal Genetic Traits,” which is exclusively licensed to Illumina from Sequenom, Inc.

Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the UK against Premaitha accusing its Iona test of infringing European Patent (UK) 0 994 963 B2, European Patent (UK) 1 981 995 B1, European Patent (UK) 2 183 693 B1, European Patent (UK) 2 385 143 B1 and European Patent (UK) 2 514 842 B1. Those suits remain pending.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ILLUMINA
10/19 ILLUMINA : to Announce Third Quarter 2017 Financial Results on Tuesday, October ..
10/19ILLUMINA, INC. : quaterly earnings release
10/16 ILLUMINA : Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow
10/12 ILLUMINA : Patent Issued for Fluidic System for Reagent Delivery to a Flow Cell ..
10/11 ILLUMINA : purchase of the Illumina Care Advantage Plan to perform routine maint..
10/10 ILLUMINA : to Announce Third Quarter 2017 Financial Results on Tuesday, October ..
10/06 ILLUMINA : D-Notice of Intent to Sole Source - Subscription License Annual Renew..
09/27 ILLUMINA : Annual Service Agreement on Illumina Equiment
09/26 ILLUMINA : MILITARY $159,208 Federal Contract Awarded to Illumina
09/22 ILLUMINA : $19.5 Million Federal Contract Awarded to Illumina
More news
News from SeekingAlpha
10/22 A Better Approach To Portfolio Construction For Your Clients
10/17 PacBio Is A DNA Sequencing Standout
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
10/11 Seeking Alpha? Here's Alpha
10/11 Gene Sequencing, The Driver Of Personalized Medicine
Financials ($)
Sales 2017 2 684 M
EBIT 2017 645 M
Net income 2017 792 M
Finance 2017 821 M
Yield 2017 -
P/E ratio 2017 38,97
P/E ratio 2018 51,41
EV / Sales 2017 11,1x
EV / Sales 2018 9,67x
Capitalization 30 705 M
Chart ILLUMINA
Duration : Period :
Illumina Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Technical analysis trends ILLUMINA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 193 $
Spread / Average Target -8,0%
EPS Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Ostadan Omead Executive VP-Operations, Products & Strategy
Sam A. Samad Chief Financial Officer & Senior Vice President
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA60.25%30 705
THERMO FISHER SCIENTIFIC INC.34.10%77 329
DANAHER16.64%63 154
INTUITIVE SURGICAL67.64%41 191
BOSTON SCIENTIFIC CORPORATION36.48%40 738
ROYAL PHILIPS20.29%39 253